The North America Urinalysis Test Market should witness market growth of 5.1% CAGR during the forecast period (2023-2029).
Men and women both have urinary tract infections, one of the most prevalent types of illnesses. The use of urinalysis tests in the diagnosis of renal diseases, diabetes, and urinary tract infections is on the rise due to the increasing frequency of these infections. Due to the rising prevalence of chronic diseases and the growing significance of preventative healthcare, there is also an increase in demand for improved urinalysis instruments. Patients may keep an eye on their health with the help of these gadgets, which eliminates the need for regular doctor's appointments which is aiding the market's expansion.
A growing emphasis on preventive healthcare and early disease identification also supports the market expansion of urine tests. Key companies in the urinalysis market are anticipated to find new growth possibilities in developing nations. The burden of chronic diseases is growing, the healthcare system has improved, there are many patients, and people have more disposable income. Governments also conduct screening programs for the early diagnosis of illnesses, including renal and urinary problems. The demand for urine testing is anticipated to increase as the number of these programs increases.
Approximately 37 million adults in the United States, which is more than one in seven, are affected by chronic kidney disease (CKD). In addition, people with high blood pressure or diabetes are at a heightened risk of developing CKD, which is the primary cause of kidney disease. One in five patients with high blood pressure and one in three people with diabetes both have kidney damage. Heart disease and a family history of renal failure are two additional risk factors for kidney disease. Even though the renal disease is common in the US, up to 90% of those who have CKD are unaware of their condition. Many people don't become aware of their kidney illness until it is highly advanced since early-stage kidney disease frequently has no symptoms.
The US market dominated the North America Urinalysis Test Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $1,227.4 Million by 2029. The Canada market is poised to grow at a CAGR of 7% during (2023-2029). Additionally, The Mexico market should witness a CAGR of 6.8% during (2023-2029).
Based on Product, the market is segmented into Consumables and Instruments. Based on Application, the market is segmented into Disease Screening and Pregnancy & Fertility. Based on End-user, the market is segmented into Diagnostic Laboratories, Hospitals & Clinics and Homecare. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Cardinal Health, Inc., Siemens Healthineers AG (Siemens AG), ACON Laboratories, Inc., Sysmex Corporation, Bio-Rad Laboratories, Inc., Arkray, Inc., Abbott Laboratories, Danaher Corporation, F. Hoffmann-La Roche Ltd., and Becton, Dickinson and Company.
Men and women both have urinary tract infections, one of the most prevalent types of illnesses. The use of urinalysis tests in the diagnosis of renal diseases, diabetes, and urinary tract infections is on the rise due to the increasing frequency of these infections. Due to the rising prevalence of chronic diseases and the growing significance of preventative healthcare, there is also an increase in demand for improved urinalysis instruments. Patients may keep an eye on their health with the help of these gadgets, which eliminates the need for regular doctor's appointments which is aiding the market's expansion.
A growing emphasis on preventive healthcare and early disease identification also supports the market expansion of urine tests. Key companies in the urinalysis market are anticipated to find new growth possibilities in developing nations. The burden of chronic diseases is growing, the healthcare system has improved, there are many patients, and people have more disposable income. Governments also conduct screening programs for the early diagnosis of illnesses, including renal and urinary problems. The demand for urine testing is anticipated to increase as the number of these programs increases.
Approximately 37 million adults in the United States, which is more than one in seven, are affected by chronic kidney disease (CKD). In addition, people with high blood pressure or diabetes are at a heightened risk of developing CKD, which is the primary cause of kidney disease. One in five patients with high blood pressure and one in three people with diabetes both have kidney damage. Heart disease and a family history of renal failure are two additional risk factors for kidney disease. Even though the renal disease is common in the US, up to 90% of those who have CKD are unaware of their condition. Many people don't become aware of their kidney illness until it is highly advanced since early-stage kidney disease frequently has no symptoms.
The US market dominated the North America Urinalysis Test Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $1,227.4 Million by 2029. The Canada market is poised to grow at a CAGR of 7% during (2023-2029). Additionally, The Mexico market should witness a CAGR of 6.8% during (2023-2029).
Based on Product, the market is segmented into Consumables and Instruments. Based on Application, the market is segmented into Disease Screening and Pregnancy & Fertility. Based on End-user, the market is segmented into Diagnostic Laboratories, Hospitals & Clinics and Homecare. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Cardinal Health, Inc., Siemens Healthineers AG (Siemens AG), ACON Laboratories, Inc., Sysmex Corporation, Bio-Rad Laboratories, Inc., Arkray, Inc., Abbott Laboratories, Danaher Corporation, F. Hoffmann-La Roche Ltd., and Becton, Dickinson and Company.
Scope of the Study
By Product
- Consumables
- Instruments
By Application
- Disease Screening
- Pregnancy & Fertility
By End-user
- Diagnostic Laboratories
- Hospitals & Clinics
- Homecare
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Cardinal Health, Inc.
- Siemens Healthineers AG (Siemens AG)
- ACON Laboratories, Inc.
- Sysmex Corporation
- Bio-Rad Laboratories, Inc.
- Arkray, Inc.
- Abbott Laboratories
- Danaher Corporation
- F. Hoffmann-La Roche Ltd.
- Becton, Dickinson and Company
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. North America Urinalysis Test Market by Product
Chapter 5. North America Urinalysis Test Market by Application
Chapter 6. North America Urinalysis Test Market by End User
Chapter 7. North America Urinalysis Test Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Cardinal Health, Inc.
- Siemens Healthineers AG (Siemens AG)
- ACON Laboratories, Inc.
- Sysmex Corporation
- Bio-Rad Laboratories, Inc.
- Arkray, Inc.
- Abbott Laboratories
- Danaher Corporation
- F. Hoffmann-La Roche Ltd.
- Becton, Dickinson and Company
Methodology
LOADING...
